Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
CAI US​

Caris Life Sciences, Inc.(CAI US)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Caris Life Sciences, Inc. — Company Profile

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UQ
CEO
David Dean Halbert
Headquarters
Irving, TX, US
IPO Date
Jun 18, 2025
Employees
1,846
Website
www.carislifesciences.com

Key Metrics

Price
$28.30
Market Cap
$8.00B
Revenue (TTM)
$216.17M
Net Income (TTM)
$-510000.00
EPS (TTM)
-0.00
P/E (TTM)
235.41
P/B (TTM)
13.48
Dividend Yield
0.00%
ROE (TTM)
-0.09%
ROA (TTM)
-0.04%
Operating Margin
2.44%
Beta
1.42

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Website
www.carislifesciences.com
Location
Irving, TX, US
Phone866 771 8946
Employees1,846
CEODavid Dean Halbert
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateJun 18, 2025

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(127)

Expand
  • 4Statement of changes in beneficial ownership23 Sep
  • 144Denton John Russel22 Sep
  • 4Statement of changes in beneficial ownership17 Sep
  • 144Brille Brian J17 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 4Statement of changes in beneficial ownership4 Sep
  • 144Spetzler David Baxley4 Sep
  • 144Spetzler David Baxley3 Sep
  • 144POSTE GEORGE24 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • SC 13G/ACaris Life Sciences, Inc.12 Aug
  • 144POSTE GEORGE7 Aug
  • SC 13G/ACaris Life Sciences, Inc.7 Aug

News

  • Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection19 Oct
  • Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 202615 Oct
  • Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 202614 Oct
  • Caris Life Sciences, Inc. $CAI Shares Newly Bought by City Center Advisors LLC8 Oct
  • IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months2 Oct
  • Caris Life Sciences: Diagnostics Growth With Room To Run17 Sep
  • Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?16 Sep
  • Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect8 Sep
  • Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer2 Sep
  • Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice27 Aug
  • Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer27 Aug
  • Caris Life Sciences: Guidance Raised, Valuation Still Attractive6 Aug
  • Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript5 Aug
  • Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q25 Aug
  • Caris Life Sciences Q2 Earnings Call Highlights5 Aug
  • Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance5 Aug

Mentions in Filings

  • … unology-focused precision-medicine and diagnostics companies, including Aqtual, Prometheus Laboratories, Immunai, and CytoReason, as well as broader molecular-diagnostics and precision-medicine companies, including <strong>Caris Life Sciences</strong>, Foundation Medicine, an affiliate of Roche, Tempus AI, Labcorp, QIAGEN, Myriad Genetics and NeoGenomics. We also compete with biopharmaceutical companies that develop biomarker and companion-diagnostic capabilities …
    Chemomab Therapeutics Ltd.Caris Life Sciences, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·19 Oct
  • … unology-focused precision-medicine and diagnostics companies, including Aqtual, Prometheus Laboratories, Immunai, and CytoReason, as well as broader molecular-diagnostics and precision-medicine companies, including <strong>Caris Life Sciences</strong>, Foundation Medicine, an affiliate of Roche, Tempus AI, Labcorp, QIAGEN, Myriad Genetics and NeoGenomics. We also compete with biopharmaceutical companies that develop biomarker and companion-diagnostic capabilities …
    Chemomab Therapeutics Ltd.Caris Life Sciences, Inc.·S-4 - Registration statement (business combination)·Q3 26·25 Sep
  • … c-25 Distribution of Trading Volume Since IPO # of shares (in mm) % distribution 1,177 878 459 39% 414 29% 75 30 15% 14% 2% 1% $20 - $35 $35 - $50 $50 - $65 $65 - $80 $80 - $95 $95 - $110 Source: FactSet as of 1/30/26. 6 (1) Selected mid-cap tools / diagnostics companies include Bio-Rad Laboratories, Bio-Techne, Revvity, QIAGEN, Guardant Health, Agilent, Illumina, Natera, <strong>Caris Life Sciences</strong>, Quest Diagnostics, Labcorp, GeneDx, and Veracyte. ---
    Personalis, Inc.Caris Life Sciences, Inc.·EX-99.(C)(4) - SC 13E3 - Going private transaction statement·Q3 26·31 Aug
  • … ompanies Natera, Inc. $34,200 $80 $1,088 ($1,008) $33,193 — 25.0% 1.30 1.30 Guardant Health, Inc. 20,969 491 1,103 (612) 20,357 — 25.0% 1.44 1.44 (3) Billiontoone, Inc. 5,698 81 537 (457) 5,241 — 25.0% 0.86 0.86 <strong>Caris Life Sciences, Inc.</strong> 5,199 400 822 (422) 4,776 — 25.0% 1.36 1.36 4,220 – 439 (439) 3,781 — 25.0% 1.61 1.61 Veracyte, Inc. Grail, Inc. 3,372 – 823 (823) 2,549 — 25.0% 1.86 1.86 Adaptive Biotechnologies Corporation 3,152 8 237 (229) 2, …
    Personalis, Inc.Caris Life Sciences, Inc.·EX-99.(C)(8) - SC 13E3 - Going private transaction statement·Q3 26·31 Aug
  • … (1,103) 24,034 — 25.0% 1.44 1.44 TOUCAN 9,850 1,449 844 605 10,455 6.1% 26.5% 2.14 2.05 (3) Billiontoone, Inc. 7,133 81 537 (457) 6,677 — 25.0% 0.99 0.99 5,005 — 439 (439) 4,566 — 25.0% 1.60 1.60 Veracyte, Inc. <strong>Caris Life Sciences, Inc.</strong> 4,951 400 822 (422) 4,529 — 25.0% 1.28 1.28 Adaptive Biotechnologies Corporation 4,004 353 364 (11) 3,993 — 25.0% 1.71 1.71 Grail, Inc. 3,794 — 933 (933) 2,861 — 25.0% 1.86 1.86 2,292 — 207 (207) 2,084 — 25.0% 1. …
    Personalis, Inc.Caris Life Sciences, Inc.·EX-99.(C)(17) - SC 13E3 - Going private transaction statement·Q3 26·31 Aug
  • … le Companies $29,797 $80 $1,042 ($962) $28,835 — 25.0% 1.24 1.24 Natera, Inc. Guardant Health, Inc. 14,807 893 1,300 (407) 14,400 — 25.0% 1.14 1.14 Tempus Ai, Inc. 9,802 1,289 875 414 10,216 4.2% 25.0% 2.19 2.12 <strong>Caris Life Sciences, Inc.</strong> 6,335 400 802 (402) 5,933 — 25.0% 1.00 1.00 4,779 – 1,014 (1,014) 3,765 — 25.0% 1.83 1.83 Grail, Inc. (3) Billiontoone, Inc. 4,578 81 482 (400) 4,178 — 25.0% (0.04) (0.04) Veracyte, Inc. 2,845 – 366 (366) 2,479 — …
    Personalis, Inc.Caris Life Sciences, Inc.·EX-99.(C)(5) - SC 13E3 - Going private transaction statement·Q3 26·31 Aug

Key Stats

Trading

Px/Chg 1D$28.30 / -0.18%
Prev Close$25.07
% of 52Wk H67.46%
Avg Volume2.65M
Beta1.42
Mkt Cap8.00B
FD Mkt Cap7.02B

Float

Shrs Out/Float282.68M / 11.29M
Short Float1.26%
Days to Cover4.33
Stock Repurchased$0.00

Current Valuation

EV7.61B
EV/EBITDA72.83
EV/Sales8.39
P/B13.48
P/S8.82
FCF Yield0.28%
ROE-0.09%
ROA-0.04%
Current Ratio7.05

Estimates

P/E235.41
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-7,898.36404.77-16,201.48
Price / Sales75.74113.2638.22
Price / Book Value35.6957.4613.92
Price / Free Cash Flow601.25835.82366.68
ENTERPRISE VALUE METRICS
Enterprise Value20,313.732,754.87,872.6
Enterprise Value / Sales74.13111.8336.42
Enterprise Value / EBITDA548.22335.59760.86
Enterprise Value / EBIT920.74351.021,490.45

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '20Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue28.9%294.0258.5306.1412.3812.0
Gross Income30.8%184.280.089.3178.8539.2
EBITDA-54%254.5-245.9-260.8-183.011.4
EBIT—143.8-294.1-309.8-231.9-11.2
Net Income—27.7-320.8-341.4-281.9-538.0
EPS (Diluted)—1.55-1.57-1.82-2.70-1.90
BALANCE SHEET
Cash & ST Inv56.7%132.5409.6121.666.2800.1
Total Assets-19%2,612.6717.4412.9343.71,125.7
Total Liabilities-26.8%1,910.42,419.52,557.92,842.6548.4
Total Shareholder Equity-4.8%702.2-1,702.1-2,145.0-2,498.8577.3
CASH FLOW
Net Operating Cash Flow-26%277.0-285.7-276.1-245.283.2
Cap Ex-47.8%-219.5-42.3-22.3-8.4-16.3
Free Cash Flow3.8%57.6-328.0-298.4-253.666.9

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)31.63
Basic Shares282.68
Market Cap8,941.2
Diluted Shares282.56
Fully Diluted Shares Outstanding282.56
Fully Diluted Market Cap8,937.4
+Consolidated Debt431.0
−In-the-Money Convertible Debt—
+Capital Leases43.5
+Operating Leases—
−Cash & Equivalents-821.1
−Short-term Investments-2.3
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value8,551.0

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US

DiaSorin S.p.A.

DSRLF US